Download PDF
Dtsch Med Wochenschr 2019; 144(14): 957-963
DOI: 10.1055/a-0746-4002
Dossier
© Georg Thieme Verlag KG Stuttgart · New York

Intestinales Mikrobiom und kardiovaskuläre Erkrankungen

Gut Microbiome and Cardiovascular Disease
Hans-Michael Steffen
,
Münevver Demir
Further Information

Publication History

Publication Date:
16 July 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Aging, physical activity, bodyweight and diet are well established risk factors for cardiovascular disease. For all of these factors a great impact on the intestinal microbiome has been described. The current review will discuss available data regarding the role of the gut microbiome in regulating blood pressure, vascular function and its possible contribution to atherosclerosis and heart failure.

Alter, Ausmaß körperlicher Aktivität, Körpergewicht und bestimmte Nahrungsbestandteile sind 4 anerkannte Einflussgrößen für das Auftreten kardiovaskulärer Erkrankungen. Das sind aber auch genau die Faktoren, für die ein Effekt auf das intestinale Mikrobiom beschrieben wurde. Könnte es also sein, dass die intestinale Dysbiose die eigentliche treibende Kraft hinter diesen kardiovaskulären Risikofaktoren ist?

Schlüsselwörter

intestinales Mikrobiom - arterielle Hypertonie - Atherosklerose - KHK - Herzinsuffizienz

Key words

gut microbiome - arterial hypertension - atherosclerosis - CAD - heart failure
 

  • Literatur

  • 1 Li J, Jia H, Cai X. et al. An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol 2014; 32: 834-841
    CrossrefPubMedGoogle Scholar
  • 2 Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease – current status and future directions. J Dig Dis 2015; 16: 541-557
    CrossrefPubMedGoogle Scholar
  • 3 Turnbaugh PJ, Ley RE, Mahowald MA. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031
    PubMedGoogle Scholar
  • 4 Yang T, Santisteban MM, Rodriguez V. et al. Gut dysbiosis is linked to hypertension. Hypertension 2015; 65: 1331-1340
    CrossrefPubMedGoogle Scholar
  • 5 Miyamoto J, Kasubuchi M, Nakajima A. et al. The role of short-chain fatty acid on blood pressure regulation. Curr Opin Nephrol Hypertens 2016; 25: 379-383
    CrossrefPubMedGoogle Scholar
  • 6 Marques FZ, Nelson E, Chu PY. et al. High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice. Circulation 2017; 135: 964-977
    CrossrefPubMedGoogle Scholar
  • 7 Bartolomaeus H, Balogh A, Yakoub M. et al. The Short-Chain Fatty Acid Propionate Protects from Hypertensive Cardiovascular Damage. Circulation 2018. doi:10.1161/CIRCULATIONAHA.118.036652. [Epub ahead of print]
    PubMedGoogle Scholar
  • 8 Juraschek SP, Bower JK, Selvin E. et al. Plasma lactate and incident hypertension in the atherosclerosis risk in communities study. Am J Hypertens 2015; 28: 216-224
    CrossrefPubMedGoogle Scholar
  • 9 Qi YF, Aranda JM, Rodriguez V. et al. Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension – a case report. Int J Cardiol 2015; 201: 157-158
    CrossrefPubMedGoogle Scholar
  • 10 Wilck N, Matus MG, Kearney SM. et al. Salt-responsive gut commensal modulates TH17 axis and disease. Nature 2017; 551: 585-589
    PubMedGoogle Scholar
  • 11 Khalesi S, Sun J, Buys N. et al. Effect of probiotics on blood pressure. A systematic review and meta-analysis of randomized, controlled trials. Hypertension 2014; 64: 897-903
    CrossrefPubMedGoogle Scholar
  • 12 Li J, Zhao F, Wang Y. et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 2017; 5: 14 . doi:10.1186/s40168-016-0222-x
    CrossrefPubMedGoogle Scholar
  • 13 Lam V, Su J, Koprowski S. et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J 2012; 26: 1727-1735
    CrossrefPubMedGoogle Scholar
  • 14 Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 2005; 293: 2641-2547
    CrossrefPubMedGoogle Scholar
  • 15 Jie Z, Xia H, Zhong SL. et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun 2017; 8: 845 . doi:10.1038/s41467-017-00900-1
    CrossrefPubMedGoogle Scholar
  • 16 Li J, Lin S, Vanhoutte PM. et al. Akkermansia munciniphlia protects aganst athersosclerosis by preventing metabolic endotoxinemia-induced inflammation in Apoe-/- mice. Circulation 2016; 133: 2434-2446
    CrossrefPubMedGoogle Scholar
  • 17 Tang WHW, Wang Z, Levison BS. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368: 1575-1584
    CrossrefPubMedGoogle Scholar
  • 18 Heianza Y, Ma W, Manson JE. et al. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies. J Am Heart Assoc 2017; 6: e004947 . doi:10.1161/JAHA.116.004947
    PubMedGoogle Scholar
  • 19 Koeth RA, Wang Z, Levison BS. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19: 576-585
    CrossrefPubMedGoogle Scholar
  • 20 Gregory JC, Buffa JA, Org E. et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem 2015; 290: 5647-5660
    CrossrefPubMedGoogle Scholar
  • 21 Zhu W, Gregory JC, Org E. et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 2016; 165: 111-124
    CrossrefPubMedGoogle Scholar
  • 22 Wang Z, Roberts AB, Buffa JA. et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 2015; 163: 1585-1595
    CrossrefPubMedGoogle Scholar
  • 23 Koeth RA, Lam-Galvez BR, Kirsop J. et al. L-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J Clin Invest 2019; 129: 373-387
    PubMedGoogle Scholar
  • 24 Wang Z, Bergeron N, Levison BS. et al. Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-oxide metabolism and renal excretion in healthy men and women. Eur Heart J 2019; 40: 583-594
    CrossrefPubMedGoogle Scholar
  • 25 Niebauer J, Volk HD, Kemp M. et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999; 353: 1838-1842
    CrossrefPubMedGoogle Scholar
  • 26 Sandek A, Bauditz J, Swidsinski A. et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 1561-1569
    CrossrefPubMedGoogle Scholar
  • 27 Pasini E, Aquilani R, Testa C. et al. Pathogenic gut flora in patients with chronic heart failure. J Am Coll Cardiol HF 2016; 4: 220-227
    PubMedGoogle Scholar
  • 28 Luedde M, Winkler T, Heinsen FA. et al. Heart failure is associated with depletion of core intestinal microbiota. ESC Heart Fail 2017; 4: 282-290
    PubMedGoogle Scholar
  • 29 Tang WHW, Wang Z, Fan Y. et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 2014; 64: 1908-1914
    CrossrefPubMedGoogle Scholar
  • 30 Organ CL, Otsuka H, Bhushan S. et al. Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail 2016; 9: e002314 . doi:10.1161/CIRCHEARTFAILURE.115.002314
    PubMedGoogle Scholar